Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00169988 · ClinicalTrials.gov registry record · NA
Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms
A NA study of Psychotic Disorders and Prodromal Schizophrenia, sponsored by Northwell Health.
- Completed
- Registry status
- NA
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT00169988: Completed NA study of Psychotic Disorders and Prodromal Schizophrenia, sponsored by Northwell Health.
NCT00169988 is a NA study of Psychotic Disorders and Prodromal Schizophrenia that has completed, run by Northwell Health. The registered enrollment target is 8 participants, below the 255-participant average among 22 other Psychotic Disorders trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00169988, a NA study of Psychotic Disorders and Prodromal Schizophrenia, has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
The Recognition and Prevention (RAP) Program is conducting a research study comparing an antidepressant, sertraline, alone versus in combination with a second-generation antipsychotic, risperidone, to evaluate their ability to reduce unusual thoughts, suspiciousness and other unusual experiences, to improve reasoning ability, memory, attention and social skills in adolescents.
Conditions Studied
Interventions
- DRUG risperidone
- DRUG sertraline-primary
Study Locations (1)
New York
- RAP Program, Dept. of Psychiatry Research, The Zucker Hillside Hospital - Glen Oaks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2004-03 |
| Est. Completion | 2007-04 |
| Phase | NA |
What the finished NCT00169988 record still lists
NCT00169988 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 255-participant average among 22 other Psychotic Disorders trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Psychotic Disorders appearing as the primary indexed condition, and to 2 interventions - of which risperidone is the first listed.
NCT00169988 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00169988 about?
NCT00169988 is a clinical study titled "Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms". The Recognition and Prevention (RAP) Program is conducting a research study comparing an antidepressant, sertraline, alone versus in combination with a second-generation antipsychotic, risperidone, to evaluate their ability to reduce unusual thoughts, suspiciousness and other unusual experiences, to...
What is the current status of trial NCT00169988?
This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2004-03. Estimated completion is 2007-04.
What conditions does trial NCT00169988 study?
This clinical trial studies the following conditions: Psychotic Disorders, Prodromal Schizophrenia.
What interventions are being tested in trial NCT00169988?
The interventions under investigation include: risperidone (DRUG), sertraline-primary (DRUG).
Who is sponsoring clinical trial NCT00169988?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00169988 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psychotic Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00169988's enrollment target sits among peer trials
8 23rd of 22 the lowest of 22 other Psychotic Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psychotic Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of a Transdiagnostic Intervention for Adolescents at Risk for Serious Mental Illness
RECRUITING · NA
-
A Preventive Behavioral Intervention for Young Adults With Psychotic Experiences
RECRUITING · NA
-
Racial Disparities in the Expression of Paranoia
RECRUITING · NA
-
Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders
RECRUITING · NA
-
A Novel Peer-Delivered Recovery-Focused Suicide Prevention Intervention for Veterans With Serious Mental Illness
RECRUITING · NA
-
CBT-CP for Veterans With SMI
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia